CAR T-cell Therapy
A2B694 CAR T-Cells for Solid Cancers
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial tests a new immune cell therapy for adults with difficult-to-treat solid tumors. The therapy modifies the patient's own immune cells to target and kill cancer cells while protecting healthy cells. The study aims to find a safe dose and see how well it works.
Monoclonal Antibodies
Disitamab Vedotin for HER2-Positive Cancer
Recruiting1 awardPhase 2
Norwich, Connecticut
This trial is testing a new drug called disitamab vedotin (DV) on patients with advanced or metastatic cancers that have a specific marker called HER2. The drug works by finding and attaching to cancer cells, then delivering a substance to kill them. The study aims to see if DV is effective and safe for these patients. Disitamab vedotin is an antibody-drug conjugate designed for targeting HER2 that has been approved for urothelial carcinoma and gastric cancer.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
Recruiting1 awardPhase 1 & 2
Nashville, Tennessee
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
PD-L1 Inhibitor
SGN-PDL1V for Cancer
Recruiting1 awardPhase 1
San Antonio, Texas
This trial is testing a new drug, SGN-PDL1V, alone and with pembrolizumab, in patients with advanced solid tumors. The goal is to see if these treatments are safe and effective. SGN-PDL1V targets cancer cells directly, while pembrolizumab helps the immune system fight the cancer.
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Popular Filters
Trials for Ovarian Tumors Patients
Chemotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
PARP Inhibitor
Long-term Niraparib for Cancer
Recruiting1 awardPhase 2
Atlanta, Georgia
This trial provides continued access to niraparib for patients already receiving it in certain studies and aims to understand its ongoing safety. Niraparib helps stop cancer cells from repairing their DNA, which can kill the cancer. Niraparib is approved for use in ovarian cancer patients who respond to specific treatments.
Alkylating agents
Oregovomab + Chemo for Advanced Ovarian Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Monoclonal Antibodies
Platinum-based Therapy + Dostarlimab + Niraparib for Ovarian Cancer
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial is designed to compare the effectiveness of the current standard of care for ovarian cancer (SOC) with or without the addition of two new potential treatments, dostarlimab and niraparib.
Alkylating agents
Combination Therapy for Ovarian Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests niraparib alone and with other treatments in patients with ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if stopping cancer cells from repairing their DNA can help treat these cancers. Niraparib is a medication taken by mouth and is approved for use in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have responded to previous treatments.
Trials for SOC Patients
Chemotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
PARP Inhibitor
Long-term Niraparib for Cancer
Recruiting1 awardPhase 2
Atlanta, Georgia
This trial provides continued access to niraparib for patients already receiving it in certain studies and aims to understand its ongoing safety. Niraparib helps stop cancer cells from repairing their DNA, which can kill the cancer. Niraparib is approved for use in ovarian cancer patients who respond to specific treatments.
Alkylating agents
Oregovomab + Chemo for Advanced Ovarian Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Monoclonal Antibodies
Platinum-based Therapy + Dostarlimab + Niraparib for Ovarian Cancer
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial is designed to compare the effectiveness of the current standard of care for ovarian cancer (SOC) with or without the addition of two new potential treatments, dostarlimab and niraparib.
Alkylating agents
Combination Therapy for Ovarian Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests niraparib alone and with other treatments in patients with ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if stopping cancer cells from repairing their DNA can help treat these cancers. Niraparib is a medication taken by mouth and is approved for use in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have responded to previous treatments.
Trials for Metastatic Patients
Chemotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Alkylating agents
Oregovomab + Chemo for Advanced Ovarian Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Monoclonal Antibodies
Platinum-based Therapy + Dostarlimab + Niraparib for Ovarian Cancer
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial is designed to compare the effectiveness of the current standard of care for ovarian cancer (SOC) with or without the addition of two new potential treatments, dostarlimab and niraparib.
Trials for BRCA1 Positive Patients
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
Recruiting1 awardPhase 1
Iowa City, Iowa
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
Checkpoint Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
Trials for BRCA2 Positive Patients
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
Recruiting1 awardPhase 1
Iowa City, Iowa
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
Checkpoint Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
Phase 3 Trials
Alkylating agents
Oregovomab + Chemo for Advanced Ovarian Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Monoclonal Antibodies
Platinum-based Therapy + Dostarlimab + Niraparib for Ovarian Cancer
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial is designed to compare the effectiveness of the current standard of care for ovarian cancer (SOC) with or without the addition of two new potential treatments, dostarlimab and niraparib.
Trials With No Placebo
Chemotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
PARP Inhibitor
Long-term Niraparib for Cancer
Recruiting1 awardPhase 2
Atlanta, Georgia
This trial provides continued access to niraparib for patients already receiving it in certain studies and aims to understand its ongoing safety. Niraparib helps stop cancer cells from repairing their DNA, which can kill the cancer. Niraparib is approved for use in ovarian cancer patients who respond to specific treatments.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Alkylating agents
Combination Therapy for Ovarian Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests niraparib alone and with other treatments in patients with ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if stopping cancer cells from repairing their DNA can help treat these cancers. Niraparib is a medication taken by mouth and is approved for use in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have responded to previous treatments.
Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
Recruiting1 award8 criteria
Toronto, Ontario
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.